Table 2 Duodenal mRNA levels of selected genes
| Â | Â | Â | n | Messenger RNA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KIAA1199 | COX-2 | CDH1 | PPARD | GSTA1 | CASP3 | CCND1 | CTNNB1 | GSTP1 | ||||
Patient controls | Â | Â | 16 | 0.04 (0.03-0.06) | 0.05 (0.04-0.07) | 16.43 (11.54-22.14) | 0.73 (0.52-1.12) | 38.24 (27.25-51.76) | 5.31 (4.14-6.77) | 4.20 (2.71-5.95) | 26.90 (21.88-36.03) | 9.69 (6.37-15.60) |
Patients with FAP | Total | Pre-intervention | 37 | 0.05 (0.03-0.24) | 0.04 (0.03-0.05) | 13.36 (10.82-15.73) | 0.71 (0.48-0.95) | 28.16 (21.62-37.90) | 3.30 (2.46-4.68) | 3.72 (3.03-4.69) | 24.84 (19.02-28.45) | 7.64 (5.70-10.71) |
Group A: Celecoxib & UDCA | Pre-intervention | 19 | 0.04 (0.02-0.28) | 0.04 (0.03-0.06) | 13.54 (10.90-18.51) | 0.74 (0.54-1.05) | 30.30 (23.16-36.54) | 3.30 (2.47-5.21) | 3.96 (2.63-4.72) | 25.89 (19.80-31.89) | 7.59 (5.78-11.07) | |
Post-intervention | 14 | 0.04 (0.02-0.23) | 0.04 (0.03-0.05) | 13.72 (10.46-15.21) | 0.63 (0.50-1.28) | 27.13 (21.28-33.30) | 3.20 (2.88-4.11) | 3.50 (2.81-5.24) | 24.05 (20.96-30.27) | 7.36 (6.22-10.47) | ||
Group B: Celecoxib & placebo | Pre-intervention | 18 | 0.09 (0.03-0.22) | 0.03 (0.02-0.05) | 11.66 (10.28-15.42) | 0.63 (0.45-0.87) | 27.96 (19.84-39.44) | 3.30 (2.42-4.43) | 3.63 (3.18-4.63) | 21.60 (18.63-27.89) | 7.73 (5.46-10.27) | |
Post-intervention | 13 | 0.24 (0.05-0.84) | 0.05 (0.03-0.08) | 14.08 (10.79-16.87) | 0.78 (0.58-1.20) | 31.74 (21.02-47.12) | 2.94 (2.58-4.83) | 4.56 (3.09-5.56) | 25.26 (19.93-33.62) | 10.82 (7.44-16.18) | ||